Stuijt C C M, Karapinar-Çarkit F, van de Steeg-van Gompel C, van Laar T, van den Bemt B J F, Heringa M
Center of Excellence On Parkinson's Disease [Punt Voor Parkinson], Schaaksport 100, Groningen, the Netherlands.
Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
BMC Health Serv Res. 2024 Dec 18;24(1):1560. doi: 10.1186/s12913-024-12057-x.
Pharmaceutical care for patients with Parkinson's disease (PD) is complex. Specialized pharmaceutical care provided by a dedicated pharmacy team member (pharmabuddy) for these patients may reduce medication-related problems. The feasibility of this service for PD patients is unknown.
To evaluate the feasibility of a Pharmabuddy Care Service (PCS) for PD patients in primary care pharmacies.
Pharmabuddies who offered PCS were invited to fill in a questionnaire to evaluate the feasibility of PCS. Patients received a patient questionnaire and were invited for an interview. Patient records provided information on medication-related problems and interventions. Feasibility was evaluated conform four domains of Bowen's Framework. First, acceptability included patients' satisfaction ratings and experiences, Pharmabuddy impression on start and continuation of the service. Second, demand included use by patients and provision by pharmabuddies. Third, implementation/practicality: implementation indicators and barriers and facilitators from patient- and pharmabuddy perspective and fourth limited efficacy: effect of the PCS on PD symptoms, medication related problems identified and interventions from patient records.
Twenty-three (59%) patients completed the questionnaire, 9 were interviewed, 12 (67%) pharmabuddies responded. Acceptability was high among patients (mean 9.5 (SD 1.3) out of 10), 6 (50%) pharmacies (still) provided PCS. Demand: 56% of patients had 1-2 contact moments, 28% two or more. Ten pharmacies provided up to 14 patients per pharmacy with PCS, one up to 24. Implementation/practicality: important barriers were time constraints and perception of other healthcare professionals. Positive reactions from patients encouraged pharmabuddies to carry out their PCS-activities. Patients were positive about pharmabuddy's listening competency while knowledge could be improved. Limited efficacy: from patient records, 89 interventions were made in response to 93 (median 3 per patient (range 1-16)) medication related problems or questions, with 20 (87%) patients reporting a positive effect from their interaction with a pharmabuddy.
This study shows PCS is highly appreciated by responding patients and can be feasible for primary care pharmacies. Several implementation issues are still present. Future studies should focus on quantifiable effects of PCS services as well as resource and perception hurdles.
帕金森病（PD）患者的药学服务较为复杂。由专业药房团队成员（药学伙伴）为这些患者提供的专业药学服务可能会减少与药物相关的问题。这项服务对PD患者的可行性尚不清楚。
评估初级保健药房中为PD患者提供的药学伙伴关怀服务（PCS）的可行性。
邀请提供PCS的药学伙伴填写一份问卷，以评估PCS的可行性。患者收到一份患者问卷，并被邀请参加访谈。患者记录提供了与药物相关问题及干预措施的信息。根据鲍恩框架的四个领域评估可行性。首先，可接受性包括患者的满意度评分和体验、药学伙伴对服务开始和持续的印象。其次，需求包括患者的使用情况和药学伙伴的提供情况。第三，实施/实用性：从患者和药学伙伴的角度来看实施指标、障碍和促进因素；第四，有限疗效：PCS对PD症状的影响、从患者记录中识别出的与药物相关的问题及干预措施。
23名（59%）患者完成了问卷，9名患者接受了访谈，12名（67%）药学伙伴做出了回应。患者的可接受性较高（平均9.5分（标准差1.3），满分10分），6家（50%）药房（仍）提供PCS。需求：56%的患者有1 - 2次接触，28%的患者有两次或更多次接触。10家药房每家为多达14名患者提供PCS，1家为多达24名患者提供。实施/实用性：重要障碍是时间限制和其他医疗保健专业人员的看法。患者的积极反应鼓励药学伙伴开展PCS活动。患者对药学伙伴的倾听能力给予肯定，但知识水平有待提高。有限疗效：从患者记录来看，针对93个（每位患者中位数为3个（范围1 - 16个））与药物相关的问题或疑问进行了89次干预，20名（87%）患者报告与药学伙伴的互动产生了积极效果。
本研究表明，PCS受到参与患者的高度赞赏，对初级保健药房来说是可行的。仍然存在一些实施问题。未来的研究应关注PCS服务的可量化效果以及资源和认知障碍。
